Compassionate Drug
What is a “Compassionate Drug”?
A Compassionate Drug is a new drug. So, first of all one needs to know that a Compassionate Drug is a new drug. The newest there is. This is a…
Gastric cancer - Adding Bemarituzumab to chemo improves the results
Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes
Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the time until the disease recurred,…
Colorectal Cancer - Onvansertib, a Novel Oral PLK1 Inhibitor
Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option for patients with metastatic colorectal…
Ovarian, fallopian tube or primary peritoneal cancers - Keytruda, Avastin and Cyclophosphamide
Ovarian Cancer – 95% benefit with Keytruda, Avastin and Cyclophosphamide
Background Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable and effective therapies. About the…
Melanoma - Combining Remicade or Cimzia
Melanoma – Combining Remicade or Cimzia might be better
Background Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is dangerous because it can rapidly spread to other organs in the body…
Metastatic breast cancer - Xeloda plus Utidelone extends life
Metastatic Breast Cancer – Utidelone plus Xeloda prolong life
Background Patients with advanced or metastatic breast cancer have very few effective treatment options. The lack of successful therapeutic strategies is reflected by a low 5-year survival. There continues to…
Glioblastoma – A new kid on the block, MDNA55
Glioblastoma – A new kid on the block, MDNA55
Background - Glioblastoma and MDNA55 The interleukin-4 receptor–targeted immunotherapeutic MDNA55 has demonstrated improved survival and disease control in patients with recurrent Glioblastoma who are treated at high dose, irrespective of…
Glioblastoma - Keytruda plus Adenovirus
Glioblastoma – Is Keytruda combined with Virus the future?
Background A Phase 2 multi-center study was conducted to evaluate the virus, DNX-240, also called Tasadenoturev, in combination with the immunotherapy, Keytruda, in pateints with recurrent glioblastoma. Methods Patients with…
Sarcoma - Keytruda combined with Adriamycin
Advanced Sarcoma – Keytruda plus Adriamycin
Background Anthracyclines is a class of drugs used in cancer chemotherapy. A wildly used Anthracycline drug is Doxorubicin also known as Adriamycin. These drugs are used to treat many cancers,…
Liver cancer - Camrelizumab plus Rivoceranib
Liver Cancer – Camrelizumab plus Rivoceranib show promise
Background This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer. Camrelizumab is anti-PD-1 immunotherapy drug given intravenous. Rivoceranib, also known as…
- Go to the previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 15
- Go to the next page